Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SAR 447873

Next Previous
Drug Profile

SAR 447873

Alternative Names: 212-Pb-Targeted-Alpha-Emmitter-Therapy; 212Pb-AR-RMX; 212Pb-octreotate analog; AlphaMedix; Lead-212 radionuclide; ORM-2110; Pb212-octreotide analog; SAR-447873; ²¹²Pb-DOTAMTATE

Latest Information Update: 28 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AREVA Med; RadioMedix
  • Developer Orano Med; RadioMedix
  • Class Antineoplastics; Drug conjugates; Peptides; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuroendocrine tumours
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Neuroendocrine tumours

Most Recent Events

  • 28 Jun 2025 No recent reports of development identified for phase-I development in Neuroendocrine-tumours(Inoperable/Unresectable, Metastatic disease) in USA (IV, Injection)
  • 12 Sep 2024 ORM 2110 licensed to Sanofi worldwide
  • 31 May 2024 Efficacy and adverse events data from a phase-II trials in Neuroendocrine tumours presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top